Printer Friendly

Cord Blood Registry Announces Settlement of Litigation with Viacord.

SAN BRUNO, Calif., Oct. 27 /PRNewswire/ -- Cord Blood Registry ("Cbr") announced today that it has entered into a settlement agreement with Viacord, a division of Viacell, Inc. regarding litigation involving marketing and advertising claims. Under the terms of the settlement agreement, no financial payment will be made by either company, and both companies will dismiss all outstanding claims. No additional terms of the settlement were disclosed.

"We are pleased with the outcome of this settlement," said Tom Moore, CEO of Cbr.

About CBR

Cbr is the world's largest newborn stem cell bank. Cbr's laboratory has been collecting and processing newborn stem cells for family banking since 1992. The company has recorded profits and positive cash flow from its operating activities since 1999, with 106% growth in units banked for the first nine months of 2005 as compared with the first nine months of 2004. Over 350,000 units of cord blood for more than 105,000 newborns are preserved at Cbr's new 80,000-square-foot stem cell facility in Tucson, Arizona. The company's research and development is focused on advancing the collection, processing, and storage methods to deliver the highest quality sample and cell yield. Additionally, Cbr provides donated research samples which are made available for the nearly 200 research programs worldwide that are focused on cord blood stem cell expansion and cell-based therapies. For more information, visit http://www.cordblood.com/, or call 1-888-CORD BLOOD.
 Cord Blood Registry is a registered trademark of Cbr Systems, Inc.


 Contact:
 Rita Kennen
 Media Relations Manager
 650-635-1420 ext. 239
 rkennen@cordblood.com



CONTACT: Rita Kennen, Media Relations Manager of Cord Blood Registry, +1-650-635-1420, ext. 239, or rkennen@cordblood.com

Web site: http://www.cordblood.com/
COPYRIGHT 2005 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 27, 2005
Words:281
Previous Article:Katrina Forges New Consensus on Poverty.
Next Article:OSI awarded additional $400,000 in orders for components for the Royal Australian Navy's Collins class submarines.
Topics:


Related Articles
Viacord, Inc. and t. Breeders, Inc. Merge to Form ViaCell, Inc.
Umbilical Cord Blood Banking Benefits Further Validated, Reports Viacord, a division of ViaCell, Inc.
Value of Umbilical Cord Blood Stem Cells Reinforced with Recent Sibling Transplant.
Further Evidence of Transplant Success Utilizing Cord Blood Stem Cells; Sickle Cell Disease Cured with Cord Blood Stem Cell Transplants.
Viacord Recognized for 'Exceptional and Novel' Practices By the American Association of Blood Banks (AABB); AABB Cites Practices in Cord Blood...
Cord Blood Registry Files Suit Against ViaCell and Viacord for False and Misleading Advertising.
Cord Blood Registry Reports Partial Victory: Competitor Viacord Removes Challenged Claims From Its Web Site Following Lawsuit for False and...
ViaCell Announces Settlement of Litigation with CBR.
ViaCell Announces Executive Appointments in its Reproductive Health Business.
ViaCell and Children's Hospital Oakland Research Institute Expand Sibling Cord Blood Donor Program.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters